RESEARCH TRIANGLE PARK – Drug giant Eli Lilly, which is already building a new manufacturing facility in RTP, has acquired another 102 acres of land for a possible “future expansion possibility.”
“We have purchased additional land immediately adjacent to our site under construction,” Eli Lilly said in a statement to the Triangle Business Journal. “This land purchase further emphasizes our commitment to RTP and allows for future expansion opportunity.”
TBJ reported the land deal Friday afternoon.
“The company paid $33.16 million for 102 acres across three disjointed parcels in RTP next to its current holdings and upcoming pharmaceutical manufacturing facility in the park,” the newspaper said.
Lilly disclosed plans to build a plant and create more than 460 jobs in the Triangle area in January 2020 but a specific location was not disclosed until later. Diabetes drugs are to be made at the site.
Plans call for the construction of several buildings across the 110-acre site announced in May 2020 for which Lilly paid $36 million, according to a spokesperson for Parmer. “Multiple buildings for a comprehensive pharmaceutical manufacturing facility, including a quality control laboratory” are planned, added Parmer, which will act as the master developer.
“We are excited to announce our new manufacturing site in Durham,” said Myles O’Neill, senior vice president and president of Manufacturing Operations for Lilly, in a statement at the time.
Eli Lilly picks former GSK campus in RTP for $474M manufacturing plant
